Point-of-Care Diagnostic Testing for Mycobacterial Diseases (Tuberculosis)

project image


Bangor University


Healthcare and Pharmaceuticals, Life Sciences, Telehealth and Care

About The Opportunity:

Bangor University has developed technology that will deliver unique point-of-care diagnostic devices for the diagnosis of mycobacterial-related disease, including tuberculosis, based on its proprietary lipid antigen technology.


  • Point of care in developed and developing countries

Key Benefits:

  • Low cost
  • Avoidance of false positives
  • Quick results

IP Status:

The University has a range of granted patents and pending applications in this area.  Commercial rights to the IP are with a spin-out company; Diagnostig Ltd. 


Diagnostig Ltd is actively seeking equity investors.  The company and University are also looking for collaborative partners in public health and diagnostics to continue to develop the research.

See more at: